Nonalcoholic fatty liver disease: another leap forward

doi:10.1038/s41575-020-00406-0

Review

. 2021 Feb;18(2):85-86.

doi: 10.1038/s41575-020-00406-0.

Nonalcoholic fatty liver disease: another leap forward

Manal F Abdelmalek¹

Affiliations

PMID: 33420415
PMCID: PMC7791336
DOI: 10.1038/s41575-020-00406-0

Review

Nonalcoholic fatty liver disease: another leap forward

Manal F Abdelmalek. Nat Rev Gastroenterol Hepatol. 2021 Feb.

. 2021 Feb;18(2):85-86.

doi: 10.1038/s41575-020-00406-0.

Author

Manal F Abdelmalek¹

Affiliation

¹ Division of Gastroenterology and Hepatology, Department of Medicine, Duke University, Durham, NC, USA. manal.abdelmalek@duke.edu.

PMID: 33420415
PMCID: PMC7791336
DOI: 10.1038/s41575-020-00406-0

Abstract

In 2020, there have been substantial advances in nonalcoholic fatty liver disease mechanisms, diagnostics and treatment. Key developments include the identification of a cellular and tissue signature to provide new insights into pathophysiology, advancements in non-invasive diagnostics and publication of interim results of the first phase III trial to demonstrate improvement in hepatic fibrosis.

PubMed Disclaimer

Conflict of interest statement

Research funding (paid to institution): Allergan, Intercept, Madrigal, Viking, Genfit, Gilead, Galactin, Novo-Nordisk, Novartis, NGM Bio, Bristol-Myers Squibb, Genentech, Celgene, Poxel, Durect, Enyo, Inventiva, Enanta, Target Pharma, Boerhinger-Ingelheim, Hanmi. Advisory/consultancy: Allergan, Intercept, Madrigal, Novo-Nordisk, NGM Bio, Bristol-Myers Squibb, Inventiva, Boerhinger-Ingelheim, Promethera. Speaker’s bureaus: Intercept, Clinical Care Options, Fishawack, Inc, Chronic Liver Disease Foundation, Medscape.

Figures

None — Laura Marshall/Springer Nature Limited

See this image and copyright information in PMC

Cited by

Hepatoprotective effects of Xiaoyao San formula on hepatic steatosis and inflammation via regulating the sex hormones metabolism.
Mei XL, Wu SY, Wu SL, Luo XL, Huang SX, Liu R, Qiang Z. Mei XL, et al. World J Hepatol. 2024 Jul 27;16(7):1051-1066. doi: 10.4254/wjh.v16.i7.1051. World J Hepatol. 2024. PMID: 39086531 Free PMC article.
Correlation between T-Lymphocyte Subsets, Regulatory T Cells, and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver.
Wang X, Li W, Fu J, Ni Y, Liu K. Wang X, et al. Evid Based Complement Alternat Med. 2022 Jul 31;2022:6250751. doi: 10.1155/2022/6250751. eCollection 2022. Evid Based Complement Alternat Med. 2022. Retraction in: Evid Based Complement Alternat Med. 2023 Jun 21;2023:9756858. doi: 10.1155/2023/9756858. PMID: 35958908 Free PMC article. Retracted.
Extracellular and intracellular functions of coiled-coil domain containing 3.
Omari S, Lee H, Wang J, Zeng SX, Lu H. Omari S, et al. J Mol Cell Biol. 2023 Nov 27;15(6):mjad037. doi: 10.1093/jmcb/mjad037. J Mol Cell Biol. 2023. PMID: 37263799 Free PMC article.
Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations.
Gul F, Parvaiz N, Azam SS. Gul F, et al. PLoS One. 2023 Mar 31;18(3):e0283743. doi: 10.1371/journal.pone.0283743. eCollection 2023. PLoS One. 2023. PMID: 37000796 Free PMC article. Clinical Trial.
NMF typing and machine learning algorithm-based exploration of preeclampsia-related mechanisms on ferroptosis signature genes.
Liu X, Zhang D, Qiu H. Liu X, et al. Cell Biol Toxicol. 2024 Dec 21;41(1):14. doi: 10.1007/s10565-024-09963-5. Cell Biol Toxicol. 2024. PMID: 39707003 Free PMC article.

See all "Cited by" articles

References

1. Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020;73:202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
1. Angulo P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397. doi: 10.1053/j.gastro.2015.04.043. - DOI - PMC - PubMed
1. Davison BA, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. 2020 doi: 10.1016/j.jhep.2020.06.025. - DOI - PubMed
1. Segovia-Miranda F, et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat. Med. 2019;25:1885–1893. doi: 10.1038/s41591-019-0660-7. - DOI - PMC - PubMed
1. Younossi ZM, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196. doi: 10.1016/S0140-6736(19)33041-7. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020;73:202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed

[2] Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020;73:202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed

[3] Angulo P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397. doi: 10.1053/j.gastro.2015.04.043. - DOI - PMC - PubMed

[4] Angulo P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397. doi: 10.1053/j.gastro.2015.04.043. - DOI - PMC - PubMed

[5] Davison BA, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. 2020 doi: 10.1016/j.jhep.2020.06.025. - DOI - PubMed

[6] Davison BA, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. 2020 doi: 10.1016/j.jhep.2020.06.025. - DOI - PubMed

[7] Segovia-Miranda F, et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat. Med. 2019;25:1885–1893. doi: 10.1038/s41591-019-0660-7. - DOI - PMC - PubMed

[8] Segovia-Miranda F, et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat. Med. 2019;25:1885–1893. doi: 10.1038/s41591-019-0660-7. - DOI - PMC - PubMed

[9] Younossi ZM, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196. doi: 10.1016/S0140-6736(19)33041-7. - DOI - PubMed

[10] Younossi ZM, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196. doi: 10.1016/S0140-6736(19)33041-7. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nonalcoholic fatty liver disease: another leap forward

Affiliation

Nonalcoholic fatty liver disease: another leap forward

Author

Affiliation

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical